Back to Journals » Journal of Pain Research » Volume 9

The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development

Authors Fudin J, Pratt Cleary J, Schatman M

Received 4 March 2016

Accepted for publication 4 March 2016

Published 23 March 2016 Volume 2016:9 Pages 153—156

DOI https://doi.org/10.2147/JPR.S107794

Checked for plagiarism Yes

Jeffrey Fudin,1 Jacqueline Pratt Cleary,2 Michael E Schatman3

1Western New England University College of Pharmacy, Springfield, MA, 2Stratton VA Medical Center, Albany, NY, 3US Pain Foundation, Bellevue, WA, USA

With the opioid-misuse and -abuse problem on the rise, pain practitioners and lawmakers are scrambling for strategies to help mitigate opioid risks. Approaches include opioid-treatment agreements, urine drug testing, prescription-monitoring programs, assorted validated risk-assessment tools for abuse/misuse and opioid-induced respiratory depression (OIRD), biopsychosocial support, and other strategies.1–3 Nonopioid pain therapies should be considered and maximized prior to initiating opioid treatment; however, in some cases opioids are the optimal choice for both noncancer and cancer-related pain syndromes.4


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]